22
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T79721 |
GPR55 agonist 3
|
||
GPR55agonist 3 (Compound 26)作为一种高效GPR55激动剂,其EC50值针对hGPR55与rGPR55分别为0.239 nM和1.76 nM。此外,该化合物在EC50为6.2 nM的条件下可诱导β-arrestin招募至人类GPR55。 | |||
T79744 |
GPR55 agonist 4
|
||
GPR55agonist 4 (Compound 28),作为一种高选择性激动剂,对hGPR55 和 rGPR55 的EC50值分别为131 nM和1.41 nM,能有效诱导β-arrestin招募至人GPR55。 | |||
T22996 |
ML-191
|
ERK | MAPK |
ML-191 是GPR55的拮抗剂。它可以阻断溶血磷脂酰肌醇诱导的 GPR55 信号传导,在过表达 GPR55 的 U2OS 细胞中EC50=1.076 µM;它抑制 LPI 诱导ERK1/2 磷酸化的IC50=328 nM。当浓度为达到30 µM 时,可抑制 PKCβII 的受体依赖性易位。 | |||
T8571 |
ML-184
CID2440433 |
Cannabinoid Receptor | GPCR/G Protein |
ML-184 (CID2440433) 是一种选择性的GPR55激动剂(EC50: 250 nM),对 GPR55 的选择性比 GPR35、CB1 和 CB2 的高100 倍以上。它可以激活 GPR55 ,诱导 ERK1/2 磷酸化并促使PKCβII 向质膜移位。它能在体外诱导神经干细胞增殖,并加速进神经元分化。 | |||
T8975 |
PSB-SB-487
|
Cannabinoid Receptor | GPCR/G Protein |
PSB-SB-487 是 GPR55 的拮抗剂。 | |||
T4478 |
CID 16020046
C390-0219 |
Cannabinoid Receptor | GPCR/G Protein |
CID 16020046 (C390-0219) 是一种选择性 GPR55 拮抗剂,在酵母中抑制 GPR55 组成型活性,IC50 为 0.15 μM。它抑制 GPR55 介导的 Ca2+信号传导和 GPR55 介导的 ERK1/2 磷酸化,可降低内皮细胞的伤口愈合,参与血小板功能的调节。 | |||
T22103 |
ML-193
CID 1261822 |
Cannabinoid Receptor | GPCR/G Protein |
ML-193 (CID 1261822) 是一种有效的选择性GPR55拮抗剂,IC50值为 221 nM,对 GPR55 的选择性比 GPR35、CB1 和 CB2 高 27 倍以上,可改善帕金森病 (PD) 大鼠的运动和感觉运动缺陷。 | |||
T1915 |
AM251
|
Cannabinoid Receptor; GPR | Endocrinology/Hormones; GPCR/G Protein |
AM251 是一种选择性大麻素1 受体拮抗剂,IC50=8 nM,是一种 GPR55 的激动剂,EC50=39 nM。 | |||
T33452 |
ML192
ML-192,CID1434953,CID 1434953,ML 192,CID-1434953 |
Cannabinoid Receptor; GPR; Arrestin | Endocrinology/Hormones; GPCR/G Protein |
ML192 (CID1434953) 是一种具有选择性的 GPR55 配体拮抗剂。ML192 是一种抑制剂,可抑制 β-arrestin 转运、ERK1/2 磷酸化和 PKCβII 易位。 | |||
T23097 |
O-1602
O1602,O 1602 |
Cannabinoid Receptor; Calcium Channel | GPCR/G Protein; Membrane transporter/Ion channel; Metabolism |
O-1602 是一种新型 GPR55 激动剂,是一种非典型大麻素,与中枢神经系统和肥胖有关,是治疗膀胱炎的候选化合物。O-1602通过小鼠GPR55 的 PI3激酶/ Akt / SREBP-1c信号传导促进肝脂肪变性。O-1602以GPR3非依赖性方式诱导Hep55B细胞中的细胞内钙升高。 | |||
T22539 |
Abn-CBD
|
Others | Others |
GPR55 cannabinoid receptor agonist | |||
T27017 |
CID1792197
CID 1792197,CID-1792197 |
||
CID1792197 is a selective agonist of GPR55. | |||
T27480 |
GSK494581A
GSK 494581A,GSK-494581A |
||
GSK494581A is a GPR55 agonist and glycine transporter subtype 1 inhibitor. | |||
T27483 |
GSK575594A
GSK-575594A,GSK 575594A |
||
GSK575594A is a selective agonist of GPR55. | |||
T27016 |
CID1172084
CID-1172084,CID 1172084 |
||
CID1172084, a novel high-potent GPR55 agonist, interacts with cannabinoid receptors. | |||
T68688 | CID-1792579 | ||
CID-1792579 is a selective agonist of GPR55. | |||
T24939 |
Virodhamine trifluoroacetate
Virodhamine-trifluoroacetate,Virodhamine trifluoroacetate salt |
||
Virodhamine trifluoroacetate is an antagonist of endogenous cannabinoid receptor mixed that acts by being a full agonist at GPR55 and CB2 and partial antagonist at CB1. | |||
T77212 | L-α-lysophosphatidylinositol (Soy) (sodium) | ||
L-α-lysophosphatidylinositol Soy sodium 作为GPR55的内源性配体,是一种既属于内源性溶血磷脂也是内源性大麻素神经递质的化合物。 | |||
T37815 |
PM226
PM 226 |
||
Potent and selective CB2 receptor agonist (Ki = 12.8 nM; EC50 = 38.67 nM). Exhibits negligible affinity for the CB1 receptor (Ki > 40,000 nM) and no activity at the GPR55. Suppresses neuroinflammation by reducing microglial activation in a multiple sclerosis mouse model. BBB permeable; anti-inflammatory and neuroprotective. | |||
T68247 |
PSB-KD107
|
||
PSB-KD107 is an agonist of the Cannabinoid-Activated Orphan G‑Protein-Coupled Receptor GPR18. PSB-KD107 displayed significantly higher potency and efficacy than THC, determined in a GPR18-dependent β-arrestin recruitment assay, and were found to be selective versus the CB-sensitive receptors CB1, CB2, and GPR55. | |||
T69612 | PSB-KD477 | ||
PSB-KD477 is an Agonist of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18. PSB-KD477 displayed significantly higher potency and efficacy than THC, determined in a GPR18-dependent β-arrestin recruitment assay, and were found to be selective versus the CB-sensitive receptors CB1, CB2, and GPR55. Structure-activity relationships were steep, and indole substitution was crucial for biological activity. These first selective agonists, which are structurally distinct from the lipidic... | |||
T83926 |
S-Geranylgeranyl-L-glutathione
GGG |
||
S-Geranylgeranyl-L-glutathione是孤儿G蛋白偶联受体(GPCR)P2RY8的配体。该化合物在100 nM浓度下,选择性地诱导P2RY8而非鞘氨醇-1-磷酸受体2(S1P2)、GPR55、半胱氨酸白三烯受体1(CysLT1 receptor)以及CysLT2 receptor的内吞作用。在10 nM浓度下,S-Geranylgeranyl-L-glutathione抑制了表达P2RY8的WEHI-231 B细胞淋巴瘤细胞和分离的人扁桃体生发中心B细胞由趋化因子(C-X-C motif)配体12(CXCL12)诱导的迁移。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TN2268 |
Tetrahydromagnolol
|
Cannabinoid Receptor; GPR; GABA Receptor | Endocrinology/Hormones; GPCR/G Protein; Membrane transporter/Ion channel; Neuroscience |
Tetrahydromagnolol 是 Magnolol 的主要代谢产物,是一种弱的GPR55受体拮抗剂。它是选择性大麻素CB2受体激动剂,EC50为 170 nM,Ki 为 416 nM,对CB2受体的选择性比 CB1 受体高 20 倍。 | |||
T14046 |
Anandamide
花生四烯酸乙醇胺,(5Z,8Z,11Z,14Z)-N-(2-Hydroxyethyl)icosa-5,8,11,14-tetraenamide |
Cannabinoid Receptor; Endogenous Metabolite | GPCR/G Protein; Metabolism |
Anandamide ((5Z,8Z,11Z,14Z)-N-(2-Hydroxyethyl)icosa-5,8,11,14-tetraenamide) 是一种免疫调节剂,通过大麻素受体 CB1 和 CB2 起作用,还通过中枢神经系统中的其他靶点起作用,如 GPR18/GPR55。 |